MAINZ BIOMED NV (MYNZ) Stock Price & Overview
NASDAQ:MYNZ • NL0015000LC2
Current stock price
The current stock price of MYNZ is 0.8441 USD. Today MYNZ is up by 2.07%. In the past month the price decreased by -6.11%. In the past year, price decreased by -80.66%.
MYNZ Key Statistics
- Market Cap
- 7.648M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -22.36
- Dividend Yield
- N/A
MYNZ Stock Performance
MYNZ Stock Chart
MYNZ Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MYNZ. When comparing the yearly performance of all stocks, MYNZ is a bad performer in the overall market: 94.53% of all stocks are doing better.
MYNZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. MYNZ has a bad profitability rating. Also its financial health evaluation is rather negative.
MYNZ Earnings
MYNZ Forecast & Estimates
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 1591.74% is expected in the next year compared to the current price of 0.8441.
For the next year, analysts expect an EPS growth of 83.39% and a revenue growth -17.68% for MYNZ
MYNZ Groups
Sector & Classification
MYNZ Financial Highlights
Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -22.36. The EPS increased by 65.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.85% | ||
| ROE | -858.34% | ||
| Debt/Equity | 0.44 |
MYNZ Ownership
MYNZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.12 | 374.127B | ||
| AMGN | AMGEN INC | 15.59 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 16.13 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.99 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.44 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.85 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 10.99 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.3 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.71 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MYNZ
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Company Info
IPO: 2021-11-04
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN DE
Employees: 23
Phone: 496131265140
MAINZ BIOMED NV / MYNZ FAQ
What does MYNZ do?
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
What is the current price of MYNZ stock?
The current stock price of MYNZ is 0.8441 USD. The price increased by 2.07% in the last trading session.
Does MYNZ stock pay dividends?
MYNZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of MYNZ stock?
MYNZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for MAINZ BIOMED NV?
MAINZ BIOMED NV (MYNZ) currently has 23 employees.
What is MAINZ BIOMED NV worth?
MAINZ BIOMED NV (MYNZ) has a market capitalization of 7.65M USD. This makes MYNZ a Nano Cap stock.